Nanotechnology is a subject that studies, processes, and applies various functional materials, equipment, and systems, and controls substances on a nanoscale. Nanomedicine refers to its application in diagnosing, treating, preventing, and monitoring various diseases. Drugs administered through eye drops must travel a long distance to avoid various eye barriers reaching the posterior segment of the eye, to achieve the lowest drug level. This review focuses on nanotechnology-based eye disease treatment systems and highlights the obstacles affecting the drug management of eyes and nano-systems for the treatment of eye diseases. This paper summarizes the development prospect of nanotechnology and the challenges it faces in the treatment and diagnosis of ophthalmic diseases, to provide information and new ideas for the implementation of treatment and the development of a refractory eye disease management system.

1. Salud OOMdl. Blindness and visual impairment (in Spanish). 2019. Available from: https://www.who.int/es/news-room/fact-sheets/detail/blindness-and-vi-airily.

2. Meng T, Kurkani V, Simmers R, et al. Therapeutic implications of nanomedicine for ocular drug delivery. Drug Discovery Today. England: Elsevier Co., Ltd; 2019.

3. NSTC. National Nanotechnology Initiative—Leading to the next industrial revolution. Microscale Thermophysical Engineering 2000; 4(3): 205–212.

4. Guchet X. What’s in a word? The person of personalized (nano) medicine. Nanomedicine 2015; 10(20): 3167–3179.

5. Feng Y, Zhang Y, Ying C, et al. Corrigendum to ‘Nanopore-based fourth-generation DNA sequencing technology’ [GPB 144 (2015)-GPB 13/1 (4-16)]. Genomic Proteomics Boinformatics 2015; 13(6): 383.

6. Peck RW. Precision medicine is not just genomics: The right dose for every patient. Annual review of pharmacology and toxicology 2018; 58: 105–122.

7. Ventola CL. Progress in nanomedicine: Approved and investigational nanodrugs. P & T: A Peer-Reviewed Journal of Formulary Management 2017; 42(12): 742–755.

8. Xu Q, Kambanpatti SP, Kannan RM. Nanotechnology approaches for ocular drug delivery. Middle East African Journal of Ophthalmology 2013; 20(1): 26–37.

9. Kamaleddin MA. Nano-ophthalmology: Applications and considerations. Nanomedicine: Nano-technology, Biology and Medicine 2017; 13(4): 1459–1472.

10. Zabin MA, Arlow T, Ritch R, et al. Regenerative nanomedicine for vision restoration. Mayo Clinic Proceedings 2013; 88(12): 1480–1490.

11. Dartt DA, Willcox MD. Complexity of tear film: Importance in homeostasis and dysfunction during disease. Experimental Eye Research 2013; 117: 1–3.

12. Shilpa G, Sandeep J. Ocular pharmacology of tear film, dry eye, and allergic conjunctivitis. In: Whitcup S, Azar D (editors). Pharmacologic therapy of ocular disease. Handbook experimental pharmaceutical. Germany: Springer; 2016; p. 97–118.

13. Willcox MDP, Argueso P, Georgiev GA, et al. TFOS DEWS II tear film report. Ocular Surface Society 2017; 15(3): 366–403.

14. Sridhar MS. Anatomy of cornea and ocular surface. Indian Journal of Ophthalmology 2018; 66(2): 190–194.

15. Ma J, Wang Y, Wei P, et al. Biomechanics and structure of the cornea: Implications and association with corneal disorders. Survey of Ophthalmology 2018; 63(6): 851–861.

16. Williams K, Watsky M. Gap junctional communication in the human corneal endothelium and epithelium. Current Eyes Research 2002; 25(1): 29–36.

17. Kling S, Hafezi F. Corneal biomechanics—A review. Ophthalmic and Physiological Optics 2017; 37(3): 240–252.

18. Zavala J, Lopez Jaime GR, Rodriguez Barrientos CA, et al. Corneal endothelium: developmental strategies for regeneration. Eyes 2013; 27(5): 579–588.

19. Takahashi Y, Watanabe A, Matsuda H, et al. Anatomy of secretory glands in the eyelid and conjunctival: A photographic review. Ophthalmic Plastic and Reconstructive Surgery 2013; 29(3): 215–219.

20. Gibson IK. Goblet cells of the conjunctiva: A review of recent findings. Progress in Retinal and Eye Research 2016; 54: 49–63.

21. Galicia-Carreon J, Santacruz C, Hong E, et al. The ocular surface: From physiology to the ocular allergic diseases. Revista Alergia Mexico 2013; 60(4): 172–183.

22. Watson PG, Young RD. Scleral structure, organization and disease. A review. Experimental Eye Research 2004; 78(3): 609–623.

23. Davis-Silberman N, Ashery-Padan R. Iris development in vertebrates; Genetic and molecular considerations. Brain Research 2008; 1192: 17–28.

24. Civan MM, Macknight AD. The ins and outs of aueous humour secretion. Experimental Eye Research 2004; 78(3): 625–631.

25. Aliancy JF, Mamalis N, et al. Webvision: The organization of the retina and visual system. In: Kolb H, Fernandez E, Nelson R (editors). Webvision: The Organization of the Retina and Visual System. Salt Lake City UT: Webvision; 2017.

26. Assia EI, Apple DJ. Sideview analysis of lens. Ⅰ. The crystalline lens and the evacuated bag. Arch Ophthalmol 1992; 110(1): 89–93.

27. Nickla DL, Wallman J. The multifunctional choroid. Progress in Retinal and Eye Research 2010; 29(2): 144–168.

28. Mains J, Wilson CG. The vitreous humor as a barrier to nanoparticle distribution. Journal of Ocular Pharmacology and Therapeutics 2013; 29(2): 143–150.

29. Mulla A, Massey KL, Kalra J. Vitreous humor biochemical constituents: Evaluation of between-eye differences. The American Journal of Forensic Medicine and Pathology 2005; 26(2): 146–149.

30. Murthy KR, Goel R, Subbannayya Y, et al. Proteomic analysis of human vitreous humor. Clinical Proteomics 2014; 11(1): 29.

31. Willoughby CE, Ponzin D, Ferrari S, et al. Anatomy and physiology of the human eye: effects of mu-copolysaccharidoses disease on structure and function—A review. Clinical & Experimental Oph-thalmology 2010; 38(S1): 2–11.

32. Simo R, Villarroel M, Corraliza L, et al. The retinal pigment epithelium: Something more than a constituent of the blood-retinal barrier—The implica-tions for the pathogenesis of diabetic retinopathy. Journal of Biotechnology 2010; 2010: 190724.

33. Strauss O. The retinal pigment epithelium in visual function. Physiological Reviews 2005; 85(3): 845–881.

34. Sparrow JR, Hicks D, Hamel CP. The retinal pigment epithelium in health and disease. Current Molecular Medicine 2010; 10(9): 802–823.

35. Boulton M, Dayhaw-Barker P. The role of retinal pigment epithelium: Topographical variation and ageing changes. Eyes 2001; 15(Part 3): 384–389.

36. Gupta MP, Herzlich AA, Sauer T, et al. Retinal anatomy and pathology. Develop Ophthalmology 2016; 55: 7–17.

37. Harris A, Ciulla TA, Chung HS, et al. Regulation of retinal and optic nerve blood flow. Arch Ophthalmol 1998; 116(11): 1491–1495.

38. Gómez M. Nanomaterials, nanoparticles and green synthesis (in Spanish). Medicina Y Cirugia 2018; 27(2): 75–80.

39. Weng Y, Liu J, Jin S, et al. Nanotechnology-based strategies for treatment of ocular disease. Acta Pharmaceutica Sinica B 2016; 7(3): 281–291.

40. Prakash M, Dhesingh RS. Nanoparticles modified drug loaded biodegradable polymeric contact lenses for sustainable ocular drug delivery. Current Drug Delivery 2017; 14(4): 555–565.

41. Yavuz B, Bozdag Pehlivan S, Kaffashi A, et al. In vivo tissue distribution and efficacy studies for cyclosporin a loaded nano-decorated subconjunctival implants comparative study of human embryonic stem cells (hESC) and human induced pluripotent stem cells (hiPSC) as a treatment for retinal dystrophies. Drug delivery 2016: 3279–3284.

42. Pehlivan SB, Yavuz B, Calamak S. Preparation and in vivo/in vivo evaluation of cyclosporin A-loaded nanodecorated ocular implants for subconjunctival application. Journal of Pharmaceutical Science 2015; 104(5): 1709–1720.

43. Li X, Zhang Z, Chen H. Preparation and evaluation of diclofenac ophthalmic rapid prototyping nano-composite gel. International Pharmaceutical Com-pany 2013; 448(1): 96–100.

44. Li X, Zhang Z, Li J, et al. Diclofenac/biodegradable polymer micelles for ocular applications. Nanoscale 2012; 4(15): 4667–4673.

45. Salama AH, Shamma RN. Tri/tetra-block co-polymeric nanocarriers as a potential ocular delivery system of lornoxicam: In-vitro characterization, and in-vivo estimation of corneal permeation. International Journal of Pharmaceutics 2015; 492(1–2): 28–39.

46. Silva-Abreu M, Calpena AC, Espina M, et al. Optimization, biopharmaceutical profile and therapeutic efficacy of pioglitazone-loaded PLGA-PEG nanospheres as a novel strategy for ocular inflammatory disorders. Pharmaceutical Research 2018; 35(1): 11.

47. Ustundag-Okur N, Gokce EH, Bozbiik DI, et al. Novel nanostructured lipid carrier-based inserts for controlled ocular drug delivery: Evaluation of corneal bioavailability and treatment efficacy in bacterial keratitis. Experimental Operation Drug Delivery 2015; 12(11): 1791–1807.

48. Ustundag-Okur N, Gokce EH, Bozbiik DI, et al. Preparation and in vitro-in vivo evaluation of chitosan oligosaccharide lactic acid modified ofloxacin loaded ophthalmic nano structured lipid carriers modified with chitosan oligosaccharide lactate for the treatment of bacterial keratitis. European Journal of Pharmaceutical Science 2014; 63: 204–215.

49. Kaiser JM, Imai H, Haakenson JK, et al. Nanoliposomal minocycline for ocular drug delivery. Nanomedicine 2013; 9(1): 130–140.

50. Campos EJ, Campos A, Martins J, et al. Opening eyes to nanomedicine: Where we are, challenges and expectations on nanotherapy for diabetic retinopathy nanocarrier mediated retinal drug delivery: Overcoming ocular barriers to treat posterior eye diseases intraocular application of gold nanodisks optically tuned for optical coherence: Inhibitory effect on retinal neovascularization without unbearable toxicity surface plasmon-enhanced fluorescence on au nanohole array for prostate-specific antigen detection. Nanomedicine 2017; 2017: 2101–2113.

51. Honda M, Asai T, Oku N, et al. Liposomes and nanotechnology in drug development: Focus on ocular targets. International Journal of nanomedicine 2013; 8: 495–503.

52. Wong CW, Czarny B, Metselaar JM, et al. Evaluation of subconjunctival liposomal steroids for the treatment of experimental uveitis. Scientific Reports 2018; 8(1): 6604.

53. Zhang R, Qian J, Li X, et al. Treatment of experimental autoimmune uveoretinitis with intravitreal injection of infliximab encapsulated in liposomes. British Journal of Ophthalmology 2017; 101(12): 1731–1738.

54. Tsai CH, Wang PY, Lin IC, et al. Ocular drug delivery: Role of degradable polymeric nanocarriers for ophthalmic application. International Journal of Molecular Science 2018; 19(9).

55. Alhalafi AM. Application of polymers in intraocular drug delivery systems. Oman Journal of Ophthalmology 2017; 10(1): 3–8.

56. Mittal N, Kaur G. Investigations on polymeric nanoparticles for ocular delivery. Advances in Polymer Technology 2019; 2019: 1316249.

57. Yavuz B, Pehlivan SB, Unlu N. Dendrimeric systems and their applications in ocular drug delivery. Scientific World Journal 2013; 2013: 732340.

58. Kambhampati SP, Kannan RM, Zarbin Ma, et al. Dendrimer nanoparticles for ocular drug delivery nanomedicine for the treatment of retinal and optic nerve diseases low molecular weight oligochitosans for nonviral retinal gene therapy downregulation of VEGF mRNA expression by triamcinolone acetonide acetate-loaded chitosan derivative nanoparticles in human retinal pigment epithelial cells. Journal of Ocular Pharmacology and Therapeutics 2013; 29(2): 151–165.

59. Iezzi R, Guru BR, Glibina IV, et al. Dendrimer-based targeted intravitreal therapy for sustained attenuation of neuroinflammation in retinal degeneration. Biomaterials 2012; 33(3): 979–988.

60. Kang SJ, Durairaj C, Kompella UB, et al. Subconjunctival nanoparticle carboplatin in the treatment of murine retinoblastoma. Arch Ophthalmol 2009; 127(8): 1043–1047.

61. Mandal A, Goth V, Pal D, et al. Ocular pharmaco-kinetics of a topical ophthalmic nanomicellar solution of cyclosporine (Cequa (R)) for dry eye disease. Pharmaceutical Research 2019; 36(2): 36.

62. Perini G, Saettone MF, Carafa M, et al. Niosomes as carriers for ophthalmic drugs: in vitro/in vivo evaluation. Bolettino Chimico Farmaceutico 1996; 135(2): 145–146.

63. Abdelkad H, Alani AW, Alani RG. Recent advances in non-ionic surfactant vesicles (niosomes): Self-assembly, fabrication, characterization, drug delivery application and limitation. Drug Delivery. 2014; 21(2): 87–100.

64. Yadav KS, Rajpurohit R, Sharma S. Glaucoma: Current treatment and impact of advanced drug delivery systems. Life Sciences 2019; 221: 362–376.

65. Khalil RM, Abdulbari GA, Basham M, et al. Design and evaluation of proniosomes as a carrier for ocular delivery of lomefoxacin HCI. Journal of Liposome Research 2017; 27(2): 118–129.

66. Battaglia L, Serpe L, Foglietta F, et al. Application of lipid nanoparticles to ocular drug delivery. Expert Opinion on Drug Delivery 2016; 13(12): 1743–1757.

67. Gan L, Wang J, Jiang M, et al. Recent advances in topical ophthalmic drug delivery with lipid-based nanocarriers. Drug Discovery Today 2013; 18(5–6): 290–297.

68. Han S, Shen JQ, Gan Y, et al. Novel vehicle based on cubosomes for ophthalmic delivery of flurbiprofen with low irritancy and high bioavailability. Acta Pharmacologica Sinica 2010; 31(8): 990–998.

69. Huang J, Peng T, Li Y, et al. Ocular cubosome drug delivery system for timolol maleate: Preparation, characterization, cytotoxicity, Ex vivo, and in vivo evaluation. AAPS PharmSciTech 2017; 18(8): 2919–2926.

70. Hartnett TE, O’Connor AJ, Ladewig K. Cubosomes and other potential ocular drug delivery vehicles for macromolecular therapeutics. Expert Opinion on Drug Delivery 2015; 12(9): 1513–1526.

71. Gan L, Han S, Shen J, et al. Self-assembled liquid crystalline nanoparticles as a novel ophthalmic delivery system for dexamethasone: Improving preocular retention and ocular bioavailability. Interna-tional Journal of Pharmaceutics 2010; 396(1–2): 179–187.

72. Cooper RC, Yang H. Hydrogel-based ocular drug delivery system: Emerging fabrication strategies, applications, and bench-to-bedside manufacturing considerations. Journal of Control Release 2019; 306: 29–39.

73. Kirchhoff S, Godfrey AM, Brandell FP. Hydrogels in ophthalmic applications. European Journal of Pharmaceutical Biopharmaceutical 2015; 95(Pt B): 227–238.

74. Jung HJ, Abou-Jaoude M, Carbia BE, et al. Glaucoma therapy by extended release of timolol from nanoparticle loaded silicone-hydrogel contact lenses. Journal of Control Release 2013; 165(1): 82–89.

75. Wu Z, Kong B, Liu R, et al. Engineering of corneal tissue through an aligned PVA/collagen composite nanofibrous electrospun scaffold. Nanomaterials 2018; 8(2).

76. Myung D, Duhamel PE, Cochran JR, et al. Development of hydrogel-based keratoprostheses: A materials perspective. Biotechnological Progress 2008; 24(3): 735–741.

77. Zhan J, Singh A, Zhang Z, et al. Multifunctional aliphatic polyester nanofibers for tissue engineering. Biomatter 2012; 2(4): 202–212.

78. Tarun Garg G, Malik B, et al. Development and characterization of nano-fiber patch for the treatment of glaucoma. European Journal of Pharmaceutical Science 2014; 53: 10–16.

79. Nagarwal RC, Kant S, Singh PN, et al. Polymer nanoparticle system: A potential approach for ocular drug delivery. Journal of Control Release 2009; 136(1): 2–13.

80. Morrison PW, Khutoryanskiy VV. Advances in ophthalmic drug delivery. Therapeutic deliveries 2014; 5(12): 1297–1315.

81. Diebold Y, Calonge M. Applications of nanoparticles in ophthalmology. Progress in Retinal and Eye Research 2010; 29(6): 596–609.

82. Park K, Chen Y, Hu Y, et al. Nanoparticle-mediated expression of an angiogenic inhibitor ameliorates ischemia-induced retinal neovascularization and diabetes-induced retinal vascular leakage. Diabetes 2009; 58(8): 1902–1913.

83. Pozo-Rodriguez A, Delgado D, Gasco AR, et al. Lipid nanoparticles as drug/gene delivery systems to the retina. Journal of Ocular Pharmacology and Therapeutics 2013; 29(2): 173–188.

84. Lalu L, Tambe V, Pradhan D, et al. Novel nanosystems for the treatment of ocular inflammation: Current paradigms and future research directions. Journal of Controlled Release 2017: 19–39.

85. Balguri SP, Adelli GR, Majumdar S. Topical ophthalmic lipid nanoparticle fornulations (SLN, NLC) of indomethacin for delivery to the posterior segment ocular tissues. European Journal of Pharmaceutics and Biopharmaceutics 2016; 109: 224–235.

86. Zabihzadeh M, Rezaee H, Hosseini SM, et al. Improvement of dose distribution in ocular brachytherapy with (125) l seeds 20 mm COMS plaque followed to loading of choroidal tumor by gold nanoparticles. Journal of Cancer Research and Therapeutics 2019; 15(3): 137–146.

87. Wichterle O, Lim D (inventors). Crosslinked hydrophilic polymers and their products. US patent. 1965.

88. Dubard M, Bourgeois S, Andrieu V, et al. Ophthalmic drug delivery systems for antibiotherapy—A review. Pharmaceutics 2018; 10(1).

89. Dixon P, Shafor C, Gauss S, et al. Therapeutic contact lenses: A patent review. Expert Opinion on Therapeutic Patents 2015; 25(10): 1117–1119.

90. Guzman-Aranguez A, Fonseca B, Carracedo G, et al. Dry eye treatment based on contact lens drug delivery: A review. Eye & Contact Lens: Science & Clinical Practice 2016; 42(5): 280–288.

91. Maulvi FA, Patil RJ, Desai AR, et al. Effect of gold nanoparticles on timolol uptake and its release kinetics from contact lenses: In vitro and in vivo evaluation. Acta Biomaterialia 2019; 86: 350–362.

92. Yasin MN, Svirskis D, Seyfoddin A, et al. Implants for drugs delivery to the posterior segment of the eye: A focus on stimuli-response and tunable release systems. Journal of Controlled Release 2014; 196: 208–221.

93. Bernards D, Bhistitkul R, Deasi T. Zero-order sustained drug delivery to the retina from a nanoporous film device. Journal of Drug Delivery 2014; 48: 20–21.

94. Lance KD, Good SD, Mendes TS, et al. In vitro and in vivo sustained zero-order delivery of rapamycin (sirolimus) from a biodegradable intraocular device. Invest Ophthalmol Visual Science 2015; 56(12): 7331–7337.

95. Sharaf Mg, Cetinel S, Heckler L, et al. Nanotechnology-based approaches for ophthalmology applications: Therapeutic and diagnostic strategies. Asia-Pacific Journal of Ophthalmology 2014; 3(3): 172–180.

96. Bachu RD, Chowdhury P, Al-Saedi ZHF, et al. Ocular drug delivery barriers-role of nanocarriers in the treatment of anterior segment diseases. Pharmaceu-tics 2018; 10(1).

97. Campos AM, Sanchez A, Alonso MJ. Chitosan nanoparticles: A new vehicle for the improvement of the delivery of drugs to the ocular surface. Application of cyclosporine A. International Journal of Pharmacy 2001; 224(1–2): 159–168.

98. Babizhayev MA. Coated with nanomaterials intraocular lenses, ophthalmic and human body implantable devices with high catalytic antioxidant activities: A new nanotechnology strategy of peroxidase cellular enzyme mimics increasing the biocompatibility and therapeutic deployment of the medical prosthetic device. Recent Patents on Drug Delivery & Formulation 2013; 7(1): 39–65.

99. Ochiutto ML, Maranhao RC, Costa VP, et al. Nanotechnology for medical and surgical glaucoma therapy—A review. Advances in Therapy 2020; 37(1): 155–199.

100. Badiee P, Varshochian R, Rafiee Tehrani M, et al. Ocular implant containing bevacizumab-loaded chitosan nanoparticles intended for choroidal neovascularization treatment. Journal of Biomed Materials Research Part A 2018; 106(8): 2261–2271.

101. Huu VA, Luo J, Zhu J, et al. Light-responsive nanoparticle depot to control release of a small molecule angiogenesis inhibitor in the posterior segment of the eye. Journal of Controlled Release 2015; 200: 71–77.

102. Aleassa EM, Xing M, Keijzer R. Nanomedicine as an innovative therapeutic strategy for pediatric cancer. Pediatric Surgery International 2015; 31(7): 611–616.

103. Kim JH, Kim MH, Jo DH, et al. The inhibition of retinal neovascularization by gold nanoparticles via suppression of VEGFR-2 activation. Biomaterials 2011; 32(7): 1865–1871.

104. Son M, Kim D, Park KS, et al. Detection of aquaporin-4 antibody using aquaporin-4 extracellular loop-based carbon nanotube biosensor for the diagnosis of neuromyelitis optica. Biosensors Ioelectronics 2016; 78: 87–91.

105. Silva NC, Silva S, Sarmento B, et al. Chitosan nanoparticles for daptomycin delivery in ocular treatment of bacterial endophthalmitis. Drug delivery 2015; 22(7): 885–893.